Lipid supplements for reducing nerve action potentials
US11253531B2 · kind B2 · utility
0Cited by
19References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 8, 2020 |
| Grant date | Feb 22, 2022 |
| Priority date | — |
| Expiry date | May 8, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA23V2002/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of oral delivery of phospholipid/inulin compositions comprising capsules, tablets, chewable wafers or powdered material in a liquid carrier in quantities effective for treating pain from overactive neurons. The phospholipid/inulin compositions were also shown to be effective in reducing depression and intestinal malfunctions including, but not limited to, diarrhea and constipation, and improving sleep pattern. The compositions further including effective amounts of caffeine also reduces fatigue and enhances alertness and focus.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.